Replies to post #338907 on Avid Bioservices Inc (CDMO)

[Amrsto1000]

And this:


Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm” associated with COVID-19. Humanigen has completed enrollment of its 520 patient Phase 3 clinical trial of lenzilumab in hospitalized COVID-19 patients.

[ElSid18]

Amrsto1000,

I only mentioned the "whisper number" for one reason:
the analysts are in consensus that AVID will break even for
the quarter which is great! If we fall short, break-even gets
extended out into a later quarter and hurts the stock momentarily.

let's keep the bull horns sharp and wish for a breakout CC.....

Also, I think today's late action was the 6/25/2021 readjustments
to the Russell.......enjoy the weekend everyone...GLTA..